Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Zhan, Jun Kun ^a   Tan, Pan ^a   Wang, Yan Jiao ^a   Wang, Yi ^a   He, Jie Yu ^a   Tang, Zhi Yong ^a   Huang, Wu ^a   Liu, You Shuo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Arterial calcification; Diabetes; Glucagon like peptide 1; Osteoblastic differentiation; Vascular smooth muscle cells

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCEROL 2 PHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; GLP1R PROTEIN, HUMAN; GLUCAGON RECEPTOR; PEPTIDE; VENOM;

ARTERY CALCIFICATION; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; MINERALIZATION; OSTEOBLAST; PROTEIN EXPRESSION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; BONE MINERALIZATION; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR CALCIFICATION; VASCULAR SMOOTH MUSCLE;

CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PEPTIDES; RANK LIGAND; RECEPTORS, GLUCAGON; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION; VENOMS;

EID: 84964695725     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0153-4     Document Type: Article

References (42)

1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
2. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
3. Lee YS, Jun HS: Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 2014, 63:9-19.
4. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE: Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510.
5. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
6. Meloni AR, DeYoung MB, Han J, Best JH, Grimm M: Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol 2013, 12:48.
7. Paul SK, Maggs D, Klein K, Best JH: Dynamic risk factors associated with non-severe hypoglycaemia in patients treated with insulin glargine or exenatide once weekly. J Diabetes 2014, doi: 10.1111/1753-0407.12208.
8. Mafong DD, Henry RR: Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep 2008, 10:55-60.
9. Brechow A, Slesaczeck T, Münch D, Nanning T, Paetzold H, Schwanebeck U, Bornstein S, Weck M: Improving major amputation rates in the multicomplex diabetic foot patient: focus on the severity of peripheral arterial disease. Ther Adv Endocrinol Metab 2013, 4:83-94.
10. Liu YS, Lu Y, Liu W, Xie H, Luo XH, Wu XP, Yuan LQ: Liao EY:Connective tissue growth factor is a down stream mediator for preptin-induced proliferation and differentiation in human osteoblasts. Amino Acids 2010, 38:763-769.
11. Yuan LQ, Zhu JH, Wang HW, Liang QH, Xie H, Wu XP, Zhou H, Cui RR, Sheng ZF, Zhou HD, Zhu X, Liu GY, Liu YS, Liao EY: RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells. PLoS One 2011, 6:e29037.
12. Massy ZA, Drüeke TB: Vascular calcification. Curr Opin Nephrol Hypertens 2013, 22:405-412.
13. Ciceri P, Volpi E, Brenna I, Arnaboldi L, Neri L, Brancaccio D, Cozzolino M: Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. Nephrol Dial Transplant 2012, 27:122-127.
14. Zhan JK, Wang YJ, Wang Y, Wang S, Tan P, Huang W, Liu YS: The mammalian target of rapamycin signalling pathway is involved in osteoblastic differentiation of vascular smooth muscle cells. Can J Cardiol 2014, 30:568-575.
15. Zhan JK, Wang YJ, Wang Y, Tang ZY, Tan P, Huang W, Liu YS: Adiponectin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the AMPK/mTOR pathway. Exp Cell Res 2014, 323:352-358.
16. Kaden JJ, Bickelhaupt S, Grobholz R, Vahl CF, Hagl S, Brueckmann M, Haase KK, Dempfle CE, Borggrefe M: Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004, 13:560-566.
17. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM: Smooth muscle cell phenotypic transition associated with calcification upregulation of cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001, 89:1147-1154.
18. Liu H, Lu Q, Huang K: Selenium suppressed hydrogen peroxide-induced vascular smooth muscle cells calcification through inhibiting oxidative stress and ERK activation. J Cell Biochem 2010, 111:1556-1564.
19. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC: Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004, 74:103-106.
20. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
21. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000, 192:463-474.
22. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM: RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009, 104:1041-1048.
23. Aoki A, Murata M, Asano T, Ikoma A, Sasaki M, Saito T, Otani T, Jinbo S, Ikeda N, Kawakami M, Ishikawa SE: Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. Cardiovasc Diabetol 2013, 12:11.
24. Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, Guralnik JM, Bandinelli S, Zauli G: Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis 2011, 215:452-458.
25. Shan PF, Lu Y, Cui RR, Jiang Y, Yuan LQ, Liao EY: Apelin attenuates the osteoblastic differentiation of vascular smooth muscle cells. PLoS One 2011, 6:e17938.
26. Liao XB, Zhou XM, Li JM, Yang JF, Tan ZP, Hu ZW, Liu W, Lu Y, Yuan LQ: Taurine inhibits osteoblastic differentiation of vascular smooth muscle cells via the ERK pathway. Amino Acids 2008, 34:525-530.
27. Shi Y, Tohyama Y, Kadono T, He J, Miah SM, Hazama R, Tanaka C, Tohyama K, Yamamura H: Protein-tyrosine kinase Sykis required for pathogen engulfment in complement-mediated phagocytosis. Blood 2006, 107:4554-4562.
28. Callegari A, Coons ML, Ricks JL, Rosenfeld ME, Scatena M: Increased Calcification in Osteoprotegerin-Deficient Smooth Muscle Cells: Dependence on Receptor Activator of NF-κB Ligand and Interleukin 6. J Vasc Res 2014, 51:118-131.
29. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, Jia CH, Wen ZH, Jin DD, Bai XC: Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 2011, 112:2902-2909.
30. Lee SK, Kalinowski J, Jastrzebski S, Lorenzo JA: 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. J Immunol 2002, 169:2374-2380.
31. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46:3-19.
32. Xu W, Bi Y, Sun Z, Li J, Guo L, Yang T, Wu G, Shi L, Feng Z, Qiu L, Li Q, Guo X, Luo Z, Lu J, Shan Z, Yang W, Ji Q, Yan L, Li H, Yu X, Li S, Zhou Z, Lv X, Liang Z, Lin S, Zeng L, Yan J, Ji L, Weng J: Comparison of the effects on glycaemic control and ß-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). J Intern Med 2014, doi: 10.1111/joim.12293.
33. Bounthavong M, Tran JN, Golshan S, Piland NF, Morello CM, Blickensderfer A, Best JH: Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes. Diabetes Metab 2014, 40:284-291.
34. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ: Effects of exenatide vs metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 2012, 11:64.
35. Vergès B, Bonnard C, Renard E: Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 2011, 37:477-488.
36. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
37. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagonlike peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037.
38. Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Jolivette LJ, Lepore JJ, Willette RN, DeAngelis E, Jucker BM: Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat. Cardiovasc Diabetol 2013, 12:148.
39. Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV, Boulton AJ, Alexander MY: The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011, 60:2187-2196.
40. Osako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H, Miyake T, Yoshizumi M, Rakugi H, Morishita R: Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification. Arterioscler Thromb Vasc Biol 2013, 33:1287-1296.
41. Mazière C, Salle V, Gomila C, Mazière JC: Oxidized low density lipoprotein enhanced RANKL expression in human osteoblast-like cells. Involvement of ERK, NFkappaB and NFAT. Biochim Biophys Acta 2013, 1832:1756-1764.
42. Hochrainer K, Racchumia G, Anrather J: Hypo-phosphorylation leads to nuclear retention of NF-κB p65 due to impaired IκBα gene synthesis. FEBS Lett 2007, 581:5493-5499.